London, UK, January 2026 – Amadeus Capital Partners today announced that Pierre Socha, Partner, has been appointed to the Science, Industry and Translation (SIT) Committee of the Royal Society, which brings together leaders from science, industry and finance to strengthen the UK’s ability to translate world-class research into scaled companies.
The appointment comes at a critical moment for the UK innovation ecosystem, as policymakers and industry leaders seek to close the long-recognised gap between scientific discovery and commercial scale. As a memeber of the SIT Committee, Socha will advise on technology financing and commercialisation models for deep tech and healthtech companies, with a focus on early transactional capital and long-horizon growth.
Founded in 1660, The Royal Society is the UK’s national academy of sciences. The appointment builds on a long-standing relationship between the Society and Amadeus Capital Partners, which for nearly three decades has backed founders translating breakthrough research – often originating in UK and European universities – into global technology businesses.
Under the leadership of Sir Robin Saxby, Founding CEO of Arm, the SIT Committee plays a central role in ensuring the UK remains an attractive environment for high-risk, patient innovation at a time of intensified global competition.
Pierre Socha, Partner at Amadeus Capital Partners, said: “The Royal Society has been a custodian of world-leading science for centuries, and I am honoured to join the SIT Committee at a time when ideology increasingly threatens to override evidence. Safeguarding independent research and building robust translational pathways are not just economic goals; they are essential for our long-term resilience. I look forward to working with Sir Robin Saxby and the Society to ensure the UK’s most daring ideas receive the capital and clarity they need to scale globally.”
Sir Robin Saxby, Chair of the Royal Society SIT Committee, added: “Pierre’s expertise in deep tech and his track record in scaling high-complexity companies make him an invaluable addition to the SIT Committee. As we work to strengthen the UK’s position as a science superpower, his perspective as a technology investor will be vital in ensuring that our world-class research finds the translational path to transform lives.”
